Clinical trials: Hyperphosphataemia
Hyperphosphatemia
BAY 77-1931 Long-term Extension From Phase II Study
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
- Trial name
- NCT00769496
- Testing
- BAY 77-1931
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Bayer
Chronic Kidney Diseases, Hyperphosphatemia
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: How much effect AP-306 has assessed by blood phosphorus lowering; How…
- Trial name
- NCT05764590
- Testing
- AP-306, Sevelamer Carbonate
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Alebund Pharmaceuticals
Chronic Kidney Failure
Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
- Trial name
- NCT00317694
- Testing
- Fermagate
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 111 people
- Sponsor
- Ineos Healthcare Limited
Hyperphosphataemia, Chronic Kidney Disease
Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
The primary objective of this study is to assess in a post-approval clinical setting the safety profile of sevelamer carbonate (Renvela®) tablets and powder in adult hyperphosphataemic chronic kidney disease (CKD) patients not on…
- Trial name
- NCT01857024
- Testing
- sevelamer carbonate (Renvela®)
- Where
- 26 sites in Austria, Denmark and 5 more
- Volunteers
- 210 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperphosphatemia Patients on Hemodialysis
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT06745518
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- Trial name
- NCT06664125
- Testing
- JMKX003002 will be administered orally, Sevelamer carbonate
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Jemincare
Chronic Kidney Disease
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704678)
- Testing
- SBR759, Sevelamer HCl
- Where
- 15 sites in Japan, Taiwan
- Volunteers
- 203 people
- Sponsor
- Novartis Pharmaceuticals
Hyperphosphatemia, Dialysis
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis
- Trial name
- NCT00767637
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 2 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Bayer
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease, Hyperphosphatemia Undergoing Hemodialysis
Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan
The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
- Trial name
- NCT02510274
- Testing
- ASP3325
- Where
- 5 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients…
- Trial name
- NCT00567723
- Where
- 199 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Shire
Hyperphosphatemia
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and…
- Trial name
- NCT04766385
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 54 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Disease Requiring Hemodialysis
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT01521494
- Testing
- PA21
- Where
- Japan
- Volunteers
- 183 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704483)
- Testing
- SBR759, Sevelamer HCl
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Hyperphosphatemia
A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
This is a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients…
- Trial name
- NCT02688764
- Testing
- PA21 (Velphoro®), Calcium Acetate (Phoslyra®)
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 85 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Hyperphosphatemia
Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for…
- Trial name
- FOSRENOL-CAPD (NCT01412398)
- Testing
- Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
- Where
- Japan
- Volunteers
- 446 people
- Sponsor
- Bayer